Aventis Pharma Deutschland, Gmbh

University of California

Sanofi-a Ventis Deutschland Gmbh

Cordula Hopmann

Michael Kurz

Roman Sakowicz

Joachim Wink

David John Faulkner

Michael S Berdelis

Christine L Blackburn

Jozsef Aszodi

Luigi Toti

Lawrence S B Goldstein

Dominique Le Beller

Mark Brönstrup

Gerhard Seibert

Guenter Mueller

Klaus-ulrich Weithmann

Martin Knauf

Heinrich Decker

Astrid Markus-Erb

Nirogi Venkata Satya Ramakrishna

Ravi Gajanan Bhat

Lawrence Sb Goldstein

Rajendra Prakash Tanpure

Uttara Vinayak Oak

Shantilal Dayaram Naker

Erra Koteswara Satya Vijayakumar

Eyyammadichiyil Sankaranarayanan Sreekumar

Martin Albert Knauf

The present invention relates to novel hydroxyphenylundecane derivatives of the formula (I), a method for the preparation of said compounds by cultivation of the fungus, DSM 14453, and their use as pharmaceuticals, i.e. for the treatment of Alzheimer's Disease, Parkinson's Disease, Huntington's Diseases, stroke, psychosis and/or depressions.

Hydroxyphenylundecane, a process for their production and their use

The present invention relates to novel active compounds named Citrullimycines, which are obtainable by cultivation ofsp. ST 101396 (DSM 13309), and to their pharmaceutically acceptable salts and derivatives. The present invention further relates to a process for the production of the Citrullimycines, to the microorganismsp. ST 101396 (DSM 13309), to the use of the Citrullimycines and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, for example as inhibitors of the neurotensin receptor, and to pharmaceutical compositions comprising Citrullimycines or a pharmaceutically acceptable salt or derivative thereof.

Citrullimycines, a process for their production and their use as pharmaceuticals

This invention provides novel compounds derived from a marine sponge, Adocia sp., that specifically modulat kinesin activity by targeting the kinesin motor domain and mimicking the activity a microtubule. The compounds act as potent anti-mitogens are useful in a wide variety of in vitro and in vivo applications.

Kinesin motor modulators derived from the marine sponge Adocia

Amycomycin, a process for its production and its use as a pharmaceutical

The present invention relates to a compound named Percyquinnin that is obtainable by cultivating a basidiomycetes (DSM 13303), and to its pharmaceutically acceptable salts. The present invention further relates to a process for the production of Percyquinnin and to the use of Percyquinnin and its pharmaceutically acceptable salts as pharmaceuticals, in particular to their use as inhibitors of lipase.

Percyquinnin, a process for its production and its use as a pharmaceutical

The present invention relates to a compound named Vancoresmycin which is obtainable by cultivation of the microorganism HIL-006734 (DSM 12216), and to its pharmaceutically acceptable salts. The present invention further relates to a process for the production of Vancoresmycin, to the microorganism HIL-006734 (DSM 12216), to the use of Vancoresmycin and its pharmaceutically acceptable salts as pharmaceuticals, and in particular to their use as antibiotics, and to pharmaceutical compositions comprising Vancoresmycin or a pharmaceutically acceptable salt thereof.

Vancoresmycin, a process for its production and its use as a pharmaceutical

Stromelysin inhibitors

Growing community of inventors

Frankfurt am Main, Germany

Cordula Hopmann